Evaluation of Near Infrared Dyes as Markers of P-Glycoprotein Activity in Tumors by Inessa Semenenko et al.
fphar-07-00426 November 12, 2016 Time: 11:42 # 1
ORIGINAL RESEARCH


















This article was submitted to
Drug Metabolism and Transport,
a section of the journal
Frontiers in Pharmacology
Received: 20 August 2016
Accepted: 26 October 2016
Published: 15 November 2016
Citation:
Semenenko I, Portnoy E,
Aboukaoud M, Guzy S, Shmuel M,
Itzhak G and Eyal S (2016) Evaluation
of Near Infrared Dyes as Markers
of P-Glycoprotein Activity in Tumors.
Front. Pharmacol. 7:426.
doi: 10.3389/fphar.2016.00426
Evaluation of Near Infrared Dyes as
Markers of P-Glycoprotein Activity in
Tumors
Inessa Semenenko1, Emma Portnoy1, Mohammed Aboukaoud1, Serge Guzy2,3,
Miriam Shmuel1, Gal Itzhak1 and Sara Eyal1*
1 Institute for Drug Research, School of Pharmacy, The Hebrew University of Jerusalem, Jerusalem, Israel, 2 Department of
Pharmacometrics, University of Maryland, College Park, MD, USA, 3 Department of Pharmacometrics, University of
Minnesota, Minneapolis, MN, USA
Aim: The multidrug resistance protein 1 (MDR1; P-glycoprotein) has been associated
with efflux of chemotherapeutic agents from tumor cells and with poor patient prognosis.
This study evaluated the feasibility of non-invasive, non-radioactive near infrared (NIR)
imaging methodology for detection of MDR1 functional activity in tumors.
Methods: Initial accumulation assays were conducted in MDR1-overexpressing
MDCK cells (MDCK-MDR1) and control MDCK cells (MDCK-CT) using the NIR dyes
indocyanine green (ICG), IR-783, IR-775, rhodamine 800, XenoLight DiR, and Genhance
750, at 0.4 µM–100 µM. ICG and IR-783 were also evaluated in HT-29 cells in which
MDR1 overexpression was induced by colchicine (HT-29-MDR1) and their controls (HT-
29-CT). In vivo optical imaging studies were conducted using immunodeficient mice
bearing HT-29-CT and HT-29-MDR1 xenografts.
Results: ICG’s emission intensity was 2.0- and 2.2-fold higher in control versus MDR1-
overexpressing cells, in MDCK and HT-29 cell lines, respectively. The respective IR-783
control:MDR1 ratio was 1.4 in both MDCK and HT-29 cells. Optical imaging of mice
bearing HT-29-CT and HT-29-MDR1 xenografts revealed a statistically non-significant,
1.7-fold difference (p > 0.05) in ICG emission intensity between control and MDR1
tumors. No such differences were observed with IR-783.
Conclusion: ICG and IR-783 appear to be weak MDR1 substrates. In vivo, low
sensitivity and high between-subject variability impair the ability to use the currently
studied probes as markers of tumor MDR1 activity. The results suggest that, for future
use of this technology, additional NIR probes should be screened as MDR1 substrates.
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INTRODUCTION
Multidrug resistance (MDR) to chemotherapy remains a clinically challenging issue. Among the
mechanisms of MDR, the most common relies on drug eﬄux from tumor cells, mediated by ATP-
binding cassette (ABC) transporters (Szakács et al., 2006; Holohan et al., 2013; Zhang et al., 2015).
The best studied ABC transporter is the multidrug resistance protein MDR1 [P-glycoprotein (P-
gp)], encoded in humans by ABCB1 (Gottesman and Pastan, 1993; Schinkel et al., 1997). MDR1
Abbreviations: DMEM, Dulbecco’s modified Eagle’s medium; ER, eﬄux ratio; ICG, indocyanine green; NIR, near infrared;
OATP, organic anion transporting polypeptide; Papp, permeability coefficient; PET, positron emission tomography; SPECT,
single-photon emission computed tomography.
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substrates include drugs central to most chemotherapeutic
regimens, such as vinca alkaloids, anthracyclines, taxanes,
epipodophyllotoxins, and tyrosine kinase inhibitors as well as
compounds of other pharmacological classes (Mann et al.,
2015). In addition, MDR1 expression in a tumor may be a
poor prognostic indicator, representative of a more aggressive
phenotype (Amiri-Kordestani et al., 2012).
The association between MDR1 expression and patient
survival or response to chemotherapy has been best
demonstrated in patients with hematological malignancies
(Szakács et al., 2006). In adult acute myelogenous leukemia
(AML), MDR1 expression was found to be an independent
prognostic variable related to induction failure (Pallis and
Russell, 2004; van der Holt et al., 2005). Evidence for an
association between MDR1 expression and poor clinical outcome
exists also for solid tumors, such as breast cancer and sarcoma
(Szakács et al., 2006). However, in contrast to hematological
malignancies, solid tumors are much more difficult to collect
and study. Only in recent years, studies of MDR1 activity in
solid tumors have become more feasible, with the introduction
of non-invasive imaging techniques and the use of radiolabeled
substrates such as 99mTc-methoxyisobutylisonitrile (99mTc-MIBI)
and 11C-verapamil (Piwnica-Worms et al., 1993; Chen et al.,
1997; Gottesman et al., 2002; Del Vecchio et al., 2003; Eary et al.,
2011). Nevertheless, PET and SPECT scans are associated with
health risk since they involve ionizing radiation, are technically
demanding and are costly (James and Gambhir, 2012; Mann
et al., 2015, 2016).
An emerging alternative technique for in vivo tumor imaging
is NIR imaging (Arranz and Ripoll, 2015; Mann et al.,
2016). Compared to other optical imaging methods, NIR is
characterized by relatively deep tissue penetration, low toxicity,
and high signal to noise ratio (Mann et al., 2015, 2016). NIR has
been applied to the imaging of breast cancer lesions and sentinel
lymph node mapping in prostate and breast cancers, as well as
other tumor types (Sevick-Muraca, 2012). The utilization of NIR
for imaging MDR1 activity was first suggested by On et al. (2011),
with rhodamine 800 as the substrate. Later, we found that the
only FDA-approved NIR molecule, ICG, is an MDR1 substrate
(Portnoy et al., 2012). Hence, the goal of the current study was to
evaluate the feasibility of NIR imaging for identification of MDR1
overexpression in solid tumors.
MATERIALS AND METHODS
Materials
Indocyanine green was purchased from Acros Organics (Geel,
Belgium). Cell culture reagents were purchased from Biological
Industries (Beit Haemek, Israel). The RNeasy mini-isolation
kit was from Qiagen (Valencia, CA, USA). TaqMan reverse
transcription reagents and fluorescent MGB probes were from
Applied Biosystems (Foster City, CA, USA). Primary antibodies
for β-actin and C219 were from Biotest (Kfar Saba, Israel) and
the primary antibody for OATP 1A2 was from Assay BioTech
(Sunnyvale, CA, USA). Secondary horseradish peroxidase-
conjugated goat anti-rabbit and goat anti-mouse antibodies were
from Jackson ImmunoResearch (West Grove, PA, USA). The
bicinchoninic acid (BCA) protein assay kit was from Pierce
(Rockford, IL, USA). Skim milk was obtained from Difco
(Franklin Lakes, NJ, USA). Pentobarbital sodium (Pental) was
from CTS Kiryat Malachi, Israel. Heparin sodium was from
Rotexmedica (Trittau, Germany). All the other reagents were
purchased from Sigma–Aldrich (Rehovot, Israel).
Cell Culture
The Madin–Darby canine kidney (MDCK) II cells transfected
with cDNA coding for MDR1 (MDCK-MDR1) and wild-type
(MDCK-CT) cells were kindly provided by Dr. Alfred Schinkel
(The Netherlands Cancer Institute). The human colorectal
adenocarcinoma cell line HT-29 was a generous donation of
Dr. Ioav Cabantchik (The Hebrew University). MDR1 was
induced in HT-29 cells (HT-29-MDR1) by incubation of control
HT-29 cells (HT-29-CT) with 300 ng/mL colchicine in growth
medium for a minimum of 9 weeks. All cell types were grown
in Dulbecco’s modified Eagle’s phenol-free low-glucose medium
(DMEM) supplemented with 10% fetal bovine serum, 2 mM
L-glutamine, 100 units/mL penicillin, and 100 µg/mL
streptomycin at 37◦C in a 5% CO2 incubator, and HT-29-
MDR1 cells were in addition continuously incubated with
colchicine.
Animals
The experimental studies and protocols were approved by the
Animal Care and Use Committee of the Hebrew University
(Protocol # MD-12-13573) and the procedures followed were in
accordance with institutional guidelines. Male CD1-nude-white
mice (6–7 weeks old) were purchased from Harlan Laboratories
(Rehovot, Israel) and housed in the specific pathogen-free facility
(SPF) unit at the Ein Kerem campus of the Hebrew University.
The mice, weighing 31 ± 2 g, had free access to food (a standard
diet) and water and were maintained on a 12:12-h automatically
timed light/dark cycle.
Accumulation Assays
Probes chosen for these studies included two compounds
previously reported to be MDR1 substrates, ICG (Portnoy et al.,
2012) and rhodamine 800 (On et al., 2011), as well as several
additional cyanine dyes: IR-775, IR-783, XenoLight DiR, and
Genhance 750. Accumulation studies were conducted using
MDCK-CT [which express endogenous, canine MDR1 (Feng
et al., 2008)], MDCK-MDR1, HT-29-CT, and HT-29-MDR1 that
were seeded separately in 96 well plates at 8 × 104 cells/well
and reached confluence, forming monolayers. The tested probe
was dissolved in dimethyl sulfoxide (DMSO) and diluted in
DMEM (maximal final DMSO concentration in the incubation
medium 0.001%). One hundred microliter of the probe at one
of nine concentrations (range 4 × 10−7 M–1.0 × 10−4 M) was
added to each well of both MDCK-CT and MDCK-MDR1 plates.
Following 1 h incubation with the probe, cells were washed
three times with PBS and emission signal was quantified using
Cytation 3 Cell Imaging Multi Mode Reader (BioTek, Winooski,
VT, USA). In a separate set of experiments, control MDCK cells
were incubated with IR-783 (2 × 10−5 M) in 24 well plates and
Frontiers in Pharmacology | www.frontiersin.org 2 November 2016 | Volume 7 | Article 426
fphar-07-00426 November 12, 2016 Time: 11:42 # 3
Semenenko et al. Near Infrared Imaging of P-gp in Tumors
accumulation was measured as described above at the presence
or the absence of verapamil (200 µM). Plates were scanned by
Typhoon FLA 9500 biomolecular imager (GE Healthcare Life
Sciences, Piscataway Township, NJ, USA).
Permeability Assays
Transport of IR-783 across cell monolayers was evaluated as
described before (Portnoy et al., 2012). Briefly, MDCK-CT cells
or MDCK-MDR1 cells were seeded at 2 × 106 cells/well on
microporous polycarbonate membrane filters. Cells were grown
until transepithelial resistance reached 200  or more (measured
by Millicell-ERS, Millipore Corporation, Billerica, MA, USA),
with daily replacement of medium. The experiments began with
replacing the medium with fresh DMEM containing the probe
(1.25 × 10−5 M). Transport of the probes was tested for both
the apical to basolateral (A to B), and the basolateral to apical
(B to A) directions. Aliquots of 100 µL were taken from the
receiver compartments every 30 min with replacement with fresh
DMEM. Probe emission intensity was measured by the Cytation
3 Reader. The studies were performed in triplicate in a humidified
incubator on two different days. Papp and the ER were calculated
as described before (Portnoy et al., 2012).
In vivo Imaging Studies
HT-29-CT and HT-29-MDR1 xenografts were initiated by
subcutaneous injection of 2.8 × 106 cells into the flanks of the
mice. HT-29-CT and HT-29-MDR1 cells were injected to the
right and left flanks, respectively. Three weeks after grafting,
mice were subjected to optical imaging. On each study day,
10 µL/gr ICG or IR-783 (8 mg/kg or 4 mg/kg, respectively, in
10 parts DDW:two parts filtered sucrose phosphate buffer 9.3%)
was injected into the tail vein. Mice were repetitively scanned
over a time period of 90 min, while body temperature was
kept on a 37◦C platform. This period was selected based on
preliminary studies demonstrating that longer imaging periods
do not increase the sensitivity to detect differences between
control and MDR1 tumors and lead to greater mortality.
At the completion of the scans, mice were sacrificed under
pentobarbital sodium anesthesia (200 mg/mL, 350 mg/kg) and
cardiac blood samples (40 µL) were collected into heparinized
96-well plates. Subsequently, tumors were collected. Along the
collection procedure, tissue and blood samples were protected
from light and kept on ice. Immediately after that, they were
scanned by the Typhoon FLA 9500 imager, to verify the results
obtained in vivo (because the in vivo signal might potentially
reflect emission from tissues underneath the tumor). The tissues
were then frozen in liquid nitrogen and kept in −80◦C until
further analysis.
Image Analysis and Data Analysis
For analysis of probe uptake kinetics in vitro, we calculated the
area under the emission-intensity-concentration curve (AUC)
using the trapezoidal rule. Larger AUC implies lower uptake or
greater eﬄux of the probe. Due to non-linearity of the emission
intensity with regard to substrate concentrations, Emax and EC50
values are not reported.
For analysis of the in vivo dye kinetics, regions of interest
(ROIs) were drawn over the tumors (0.25 ± 0.1 cm2)
using Living Image 4.3.1 (PerkinElmer, Waltham, MA, USA).
A constant size ROI (0.1 cm2) was drawn near every tumor
and used as a reference background region as recommended
by the manufacturer of the in vivo imaging system (Caliper
LifeSciences, 2012). The emission intensity was expressed in
radiant efficiency units ([photons/second/steradian]/microwatt;
[p/s/sr]/µW). Areas under the concentration-time curve (AUC)
were calculated using Phoenix WinNonlin 6.3. The ex vivo
emission intensity was analyzed using ImageJ 1.47V (National
Institute of Health, Bethesda, MD, USA).
Quantitative Real-Time Polymerase
Chain Reaction
Analysis of mRNA levels was conducted as described before
(Rubinchik-Stern et al., 2015). Briefly, total RNA was isolated
using RNeasy mini-isolation kit. RNA integrity and purity
were verified by ND-1000 spectrophotometer (NanoDrop
Technologies, Inc). cDNA was synthesized from 2 µg of total
RNA that had A260/A280 and A230/A260 ratios of 1.8–2.0 and
2.0–2.2, respectively. Reverse transcription was performed using
TaqMan reverse transcription reagents. The reactions were run
as follows: 25◦C for 10 min, followed by 37◦C for 120 min, then
85◦C for 5 min. The real-time PCR assay was carried out with
the use of gene specific FAM-labeled fluorescent MGB probes
in StepOnePlus real-time PCR system (Applied Biosystems) on
a fast mode. Samples were run in triplicate. The reaction final
volume was 10 µL for each sample. The relative mRNA levels in
each sample were normalized to the housekeeping gene β-actin.
Changes in mRNA expression of target genes from the control
cells were expressed relative to that of the vehicle control group.
Western Blot Analysis
Several tumors were large enough to allow measurement of
both the mRNA and the protein levels of MDR1. From these
tumors, whole cell lysates were prepared as previously described
(Rubinchik-Stern et al., 2015), by tissue homogenization in
cold radioimmunoprecipitation assay (RIPA) buffer. Lysates
were subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). Stacking and separating gels were
made of 5 and 10% acrylamide, respectively. Each lane was loaded
with 20 µg protein samples of whole cell lysates. Following
separation, the proteins from the gels were transferred to
nitrocellulose membranes using a Mini Trans-Blot Cell (Bio-Rad
Laboratories, Inc.). Membranes were blocked in Tris-buffered
saline containing 0.1% Tween 20 (TBS-T) and 5% skim milk
powder and probed overnight at 4◦C with primary antibodies
against β-actin (1:1,000), P-gp (recognizes both the human and
the murine MDR1; 1:600), and OATP1A2 (SLCO1A2; 1:500).
Antibodies were diluted in 5% w/v BSA in 0.1% Tris-Buffered
Saline with Tween-20 and 0.02% sodium azide. The blots were
then incubated for 1 h with horseradish peroxidase-conjugated
secondary antibodies (goat anti-rabbit) at 1:10,000 dilutions and
developed by enhanced chemiluminescence. β-Actin was used as
the internal control.
Frontiers in Pharmacology | www.frontiersin.org 3 November 2016 | Volume 7 | Article 426
fphar-07-00426 November 12, 2016 Time: 11:42 # 4
Semenenko et al. Near Infrared Imaging of P-gp in Tumors
Statistical Analysis
Results are reported as mean ± SD, unless otherwise indicated.
Values of MDR1 and control tumors were compared using the
Wilcoxon signed rank test (InStat; GraphPad, La Jolla, CA, USA).
A p value ≤ 0.05 was considered significant.
RESULTS
In vitro Characterization of the NIR
Probes
MDR1 overexpression in HT-29-MDR1 cells was confirmed by
western blot analysis. This analysis further demonstrated that
the expression of a representative uptake transporter, OATP1A2
is not significantly altered in these cells (Figure 1). Among
the tested compounds, XenoLight and GenHance accumulated
in MDCK-CT cells only scarcely, whereas rhodamine 800
and IR-775 demonstrated a quenching phenomenon at high
concentrations (Mann et al., 2015). ICG and IR-783 accumulation
increased with the dye concentration in all cell types. Both
ICG and IR-783 appeared to accumulate to a lesser extent
in MDR1-overexpressing MDCK and HT-29 cells than in
their respective controls [Table 1; Figures 2A–D; see also
(Portnoy et al., 2012)]. At 1.25 × 10−5 M, the emission
intensity of both ICG and IR-783 in HT-29-CT cells was
1.5-fold (P < 0.01) greater compared to HT-29-MDR1 cells
(Figure 2E). The ERs of IR-783, calculated from the permeability
assays, were 1.2 and 2.0 in MDCK-CT and MDCK-MDR1
cells, respectively, resulting in a net ER of 1.7 (Figure 2F). At
the presence of verapamil, the emission intensity of control
MDCK cells incubated with IR-783 was 2.9-fold higher than
FIGURE 1 | In vitro transporter expression in HT29-CT and HT29-MDR1
(multidrug resistance protein 1) tumors. Shown are mean ± SD values of
expression (n = 3) and an immunoblot of HT-29-MDR1 and HT-29-CT
extracts. Mean relative transcript and protein levels in control tumors is set as
1. C, HT-29-CT cells; M, HT-29-MDR1 cells.
TABLE 1 | AUC of ICG and IR-783 in control and multidrug resistance
protein 1 (MDR1)-overxpressing Madin–Darby canine kidney (MDCK) and
HT-29 cells.
Compound AUC
MDCK cells HT-29 cells
MDCK-CT MDCK-MDR1 HT-29-CT HT-29-MDR1
ICG 1.2 0.6 2.9 1.3
IR-783 1.3 0.9 2.6 1.8
in cells incubated with the vehicle (Figures 2G,H). The ER
of ICG and the effect of verapamil on its accumulation have
been published before (Portnoy et al., 2012). Because ICG
and IR-783 have shown the best imaging properties among
the probes studied in vitro, they were selected for farther
evaluation.
In vivo Studies
In vivo, MDR1 tumors did not significantly differ in size from
control tumors, although variability in size across animals was
observed for both tumor types (Table 2). Optical imaging
of mice treated with ICG demonstrated tumor-specific signal
accumulation (Figure 3). Elevated emission intensity in tumors
located on the right flanks of the mice indicated higher ICG
concentrations in HT-29-CT tumors, compared to their opposing
HT-29-MDR1 tumors (Figures 3A,B). The AUC of emission
intensity calculated individually for each mouse was greater
in CT compared to MDR1 tumors, with individual CT/MDR1
AUC ratios of 2.2, 2.0, 1.8, 1.5, and 1.3 (mean 1.7; Figure 3C).
The difference in emission intensity between the two tumor
types were not significant in vivo or ex vivo (p > 0.05;
Figures 3D,E).
IR-783 accumulated mostly in the largest control tumors
(0.57 cm2, 0.65 cm2). In mice which bared these tumors
the probe accumulation appeared to be greater in control
versus MDR1 tumors (Figure 4). However, in mice baring
smaller control tumors (0.08 cm2, 0.22 cm2, 0.16 cm2), IR-783
emission intensity was greater in MDR1 than in control tumors
(Figure 4C). Hence, the mean IR-783 did not differ between
the tumor types (Figures 4D,E). No relationship was observed
between MDR1 tumor size and emission intensity (data not
shown).
Transporter Expression
RT-PCR analysis of xenograft extracts demonstrated significantly
elevated MDR1 mRNA levels in HT-29-MDR1 tumors,
indicating that these cells maintained MDR1 overexpression
in vivo (Figure 5A). Interestingly, the expression of the
murine Mdr1a that might contribute to ICG and IR-783
accumulation differed between control and the MDR1 xenografts
(Figure 5B). However, the magnitude of difference was
well below that observed for MDR1. Western blotting of
proteins from tumors that were large enough to provide
material for both mRNA and protein expression analyses
confirmed MDR1 overexpression at the protein level (∼30-fold
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FIGURE 2 | In vitro cellular accumulation of ICG and IR-783 in MDR1 and control cells. (A) ICG accumulation in Madin–Darby canine kidney (MDCK)-CT and
MDCK-MDR1 cells. (B) ICG accumulation in HT-29-CT and HT-29-MDR1 cells. (C) IR-783 accumulation in MDCK-CT and MDCK-MDR1 cells. (D) IR-783
accumulation in HT-29-CT and HT-29-MDR1. Cells were incubated for 1 h with the indicated concentrations of the tested compound (n = 16 per each
concentration). (E) ICG and IR-783 accumulation in HT-29 cells at 1.25 × 10−5 M (mean ± SD). Fluorescence intensity is presented as arbitrary units (a.u).
(F) Transfer of IR-783 across MDCK-CT and MDCK-MDR1 cell monolayers. (G) An image of control MDCK cells incubated with IR-783 (2 × 10−5 M) at the
presence or the absence of verapamil (200 µM). The experiment was repeated twice, on two different days. (H) Emission intensity of control MDCK cells following
incubation with IR-783 as described for (G; n = 8). ∗p < 0.01.
TABLE 2 | Tumor sizes on the imaging study date.
Tumor area (cm2)
ICG-treated mice IR-783-treated mice
Mouse number Control tumors MDR1 tumors Control tumors MDR1 tumors
1 0.80 0.55 0.57 0.24
2 0.29 0.32 0.65 0.08
3 0.57 0.31 0.35 0.22
4 0.13 0.32 0.25 0.16
5 0.23 0.25 0.19 0.78
Mean 0.40 0.35 0.40 0.30
SD 0.28 0.16 0.20 0.28
greater than in control tumors; Figure 5C). No correlation
was found between MDR1 expression (at either the mRNA
or the protein level) and ICG emission intensity (data not
shown).
DISCUSSION
Molecular imaging technologies are being increasingly used
for the non-invasive assessment of membrane transporter
expression and function in animal models and in humans.
Among these, PET and SPECT are being applied in the
clinic. However, both PET and SPECT involve health risk
and are technically demanding (Mann et al., 2015, 2016).
In this study we evaluated for the first time the feasibility
of utilizing an alternative method, NIR, for assessing
MDR1-mediated eﬄux transport in tumors in vivo. Our
results demonstrate the advantages and challenges of this
methodology.
Many NIR probes are characterized by poor photostability,
high plasma protein binding, and aggregation and quenching at
high concentrations (Mann et al., 2015, 2016). Indeed, some of
the compounds that we initially evaluated through accumulation
assays were excluded from further analysis because of our
concern that potential accumulation in tumors may lead to
quenching of their fluorescence. The remaining compounds, ICG
(Portnoy et al., 2012) and IR-783, had favorable accumulation
profiles and their accumulation was enhanced by the MDR1
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FIGURE 3 | Tumor emission intensity in mice treated with ICG. (A) An image of a mouse bearing control (right) and MDR1 (left) tumors treated with intravenous
8 mg/kg ICG (indicated by arrows). The time from ICG injection to image acquisition was 74 min. (B) A representative emission intensity-time curve in HT-29-CT and
HT-29-MDR1 tumors of the same mouse. (C) Individual AUC values of HT29-CT and HT29-MDR1 tumor emission intensity in ICG-treated mice. The AUC was
calculated over the first 90 min after ICG injection. (D) AUC values of in vivo control and MDR1 tumor emission intensity (n = 5). (E) ICG emission from of ex vivo
control and MDR1 tumors. Results are mean ± SD.
inhibitor verapamil. Hence, these probes were selected for
further analysis. However, the in vivo studies demonstrated
low sensitivity of the probes in detecting MDR1 activity in
tumor xenografts. ICG’s MDR1:control tumor emission intensity
ratio was 1.7 only, as compared to a 6.8-fold difference
in the probe’s ER in vitro (Portnoy et al., 2012), and the
results obtained with IR-783 were highly variable. The scaled-
down sensitivity could represent MDR1 saturation in vivo.
In addition, ICG is a marker of blood flow, which could
potentially differ between control and MDR1 tumors. This could
have led to attenuation (or enhancement) of the changes in
MDR1 activity as measured by emission intensity (Mann et al.,
2016). Furthermore, variation in blood flow between larger
and smaller tumors could have contributed to the between-
subject variability in IR-783 emission. Yet, it should be kept
in mind that even established markers of MDR1 activity have
limited sensitivity and high between-subject variability when
they are used for detecting MDR1-mediated MDR in solid
tumors. For instance, breast cancer tumors expressing high
amounts of MDR1 displayed only a 2.7-fold higher [99mTc]-
sestamibi eﬄux rate compared to tumors expressing little or
no MDR1 (Del Vecchio et al., 2003). When [11C]-verapamil
was administered to soft tissue sarcoma patients along with
markers of cellular proliferation and hypoxic volume, [11C]-
radioactivity in tumors varied between patients and with
respect to the uptake parameters of other probes in individual
patients (Eary et al., 2011). In patients with advanced lung
cancer, [11C]-docetaxel radioactivity was moderate and highly
variable between and within tumors (van der Veldt et al.,
2013).
Several limitations should be noted. Particularly, the small
animal numbers could have limited our ability to identify
differences in probe uptake between MDR1 and control tumors.
However, with the exception of one IR-783-treated animal,
the magnitude of difference in emission intensity between
MDR1 and control tumors in vivo was low. We therefore
concluded that the selected probes were not optimal for
in vivo identification of MDR1-mediated drug resistance and
did not pursue using these compounds in vivo (e.g., with
larger animal numbers and MDR1 inhibitors). This decision was
made given that in clinic, tumors are expected to present an
entire spectrum of MDR1 expression rather than a binomial
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FIGURE 4 | Tumor emission intensity in mice treated with IR-783. (A) An
image of a mouse bearing control and MDR1 tumors treated with intravenous
4 mg/kg IR-783 (indicated by arrows). The time from ICG injection to image
acquisition was 76 min. (B) An emission intensity-time curve in HT-29-CT and
HT-29-MDR1 tumors in the same mouse. (C) Area under the emission
intensity-time curve (AUC) values of HT29-CT and HT29-MDR1 tumors in
IR-783-treated mice. The AUC was calculated over the first 90 min after ICG
injection. (D) AUC values of IR-783 in vivo emission intensity in control and
MDR1 tumors (n = 4). (E) IR-783 emission from ex vivo control and MDR1
tumors. Shown are mean ± SD.
distribution and detection of MDR1 activity would be further
challenging. We used HT-29 cell xenografts as the in vivo
tumor model. Such subcutaneous xenografts have limitations,
such as the lack of appropriate tumor microenvironment and
selection for clones that are no longer representative of the
original tumor. However, these models have identified clinically
efficacious agents (Gura, 1997; Morton and Houghton, 2007)
and the tumor subcutaneous localization is advantageous for
optical imaging. We have also validated MDR1 expression
in these tumors at both the mRNA and the protein levels,
although MDR1 functionality was not proven and the level
of several additional transporters varied between control and
MDR1 tumors (albeit to a much lesser extent than that of
MDR1). Although we inoculated similar numbers of HT-29-CT
and HT-29-MDR1 cells into each mouse, the growth rate and
subsequent blood flow could have differed between MDR1 and
control tumors, as described above. Finally, ICG and IR-783
are substrates of transporters other than MDR1. In particular,
OATPs mediate the uptake of both compounds into tumor cells
(Yang et al., 2010; de Graaf et al., 2011). However, the differences
between control and MDR1 tumors in the expression of these
transporters were negligible, as compared to that in MDR1
expression.
Despite the above mentioned limitations, this study has
several important strengths. First, each mouse was used as
its own control for evaluating the impact of MDR1 on the
probe emission from the tumors. Hence, normalization to
the injected dose or plasma concentrations was unnecessary.
Second, we verified tumor MDR1 expression (or paucity
thereof) in the inoculated tumors at both the mRNA and the
protein level. Finally, we provided a proof of concept for the
existence of methodology that will allow future visualization
of MDR1 activity in tumor cells in vivo, using other NIR
probes.
CONCLUSION
This study evaluated for the first time the feasibility of
detecting MDR1-mediated MDR by the use of NIR imaging.
FIGURE 5 | MDR1 expression in HT29-CT and HT29-MDR1 tumors. (A) MDR1 mRNA levels in tumor xenografts from CT and MDR1 HT-29 cells. (B) mRNA
levels of additional transporters that may be involved in ICG and IR-783 tumor accumulation. Note the differences in the Y-scale between (A) and (B). Wilcoxon
paired test, ∗p < 0.05, ∗∗p < 0.001. (C) MDR1 protein expression in tumors resected from ICG-treated (n = 4) and IR-783-treated (n = 1) mice. The lower panel
demonstrates an immunoblot of HT-29-MDR1 and HT-29-CT xenograft extract. Mean relative transcript and protein levels in control tumors was set as 1. Also
shown are the mean ± SD values of expression. C, HT-29-CT tumors; M, HT-29-MDR1 tumors.
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In vitro, the evaluated probes were poorer MDR1 substrates,
or did not behave as substrates, as compared to fluorescent
compounds which are detectable at lower wavelengths. Initial
results with probes that were assessed in vivo demonstrate low
sensitivity to identify tumor MDR1 activity. However, screening
of additional compounds or targeted synthesis may yield better
MDR1 substrate probes that can provide a tool for non-
radioactive identification of MDR1-mediated drug resistance in
solid tumors. With further optimization, such methodologies
could be useful markers for drug selection and prognosis when
the tumors or their metastases are not deep (e.g., breast tumors
and lymph node metastases) or for tumors that can be monitored
by endoscopy. In the meantime, newly synthesized NIR probes
might be screened for their interaction with P-gp and other eﬄux
transporters prior to their use in vivo, especially if the probes are
intended for studying tumor biology.
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